Payers expected to embrace Novartis heart failure drug Entresto
This article was originally published in Scrip
Executive Summary
After the markets closed on 7 July, the FDA revealed it had approved Novartis' oral heart failure treatment Entresto (sacubitril/valsartan), which previously was known as LCZ696.